An Unusual Skin Adverse Event after Switching from Intravenous to Subcutaneous VEDOLIZUMAB Therapy in Patients with Ulcerative Colitis. (2023). Archives of Clinical and Medical Case Reports, 7(1), 77-79. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22706